<DOC>
	<DOCNO>NCT01544751</DOCNO>
	<brief_summary>The first line approach NAFLD currently base diet lifestyle modification . Aim Unit compare efficacy two different dos metformin ( 1 g/day 2 g/day ) atorvastatin ( 20 mg/day ) amelioration inflammatory cardiometabolic parameter , ultrasound sign clinical score associate liver fibrosis early-stage NAFLD non-diabetic patient .</brief_summary>
	<brief_title>Nonalcoholic Fatty Liver Disease ( NAFLD ) Pharmacological Treatment : Metformin Versus Atorvastatin</brief_title>
	<detailed_description>Non alcoholic fatty liver disease ( NAFLD ) common liver disease encompass simple steatosis non alcoholic steatohepatitis ( NASH . There currently therapy proven benefit liver disorder closely associate insulin resistance feature metabolic syndrome obesity , hyperlipidaemia type 2 diabetes mellitus . The first line approach NAFLD currently base diet lifestyle modification . However , dietary treatment limit lack compliance frequent regain weight follow-up . Aim Unit compare efficacy two different dos metformin ( 1 g/day 2 g/day ) atorvastatin ( 20 mg/day ) amelioration inflammatory cardiometabolic parameter , ultrasound sign clinical score associate liver fibrosis early-stage NAFLD non-diabetic patient . The investigator enrol obese overweight non-diabetic patient ultrasonographic diagnosis hepatic steatosis early stage ( NAFLD ) . The investigator exclude study patient clinical-biochemical ultrasound marker disease severity ( age , BMI , lipid profile , AST , ALT , Angulo , BAAT HAIR clinical fibrosis score , sign portal hypertension posterior attenuation deep liver parenchyma US ) . Patients meet eligibility criterion randomly assign one three group 12 month study treatment . The first group ( n=50 ) receive metformin ( 1g/day ) plus dietary treatment ; second group ( n=50 ) give metformin ( 2 g/day ) third group ( n=50 ) treat atorvastatin ( 20 mg/day ) . All participant followed-up 3 , 6 , 9 , 12 month interval randomization . We compare effect two dos metformin atorvastatin amelioration inflammatory ( PCR , TNF-a , IL-6 ) metabolic parameter ( lipid profile , BMI , waist circumference , fast glucose , 2-h glucose tolerance test , insulin , transaminase , adiponectin , leptin , HOMA-IR index VAI index ) . Furthermore , assess improvement drug treatment liver steatosis basis US sign ( liver echogenicity stiffness ) fibrosis score system ( Angulo , BAAT HAIR score ) . In conclusion , consider increase prevalence NAFLD strong association cardiovascular disease cancer , investigator expect identify safe pharmacological regimen , addition dietary treatment , may ameliorate even reverse liver disease underlie risk factor . This study could important social impact term preventive therapeutic intervention .</detailed_description>
	<mesh_term>Liver Diseases</mesh_term>
	<mesh_term>Fatty Liver</mesh_term>
	<mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Atorvastatin Calcium</mesh_term>
	<criteria>Age &lt; =55 BMI &lt; =40 Total cholesterol &lt; =280 mg/dl LDL &lt; =180 mg/dl Triglycerides &lt; =200 mg/dl AST ALT normal range Signs simple liver steatosis ultrasonorography . Exclusion criterion : Type 2 diabetes Heart disease Renal failure Smoking habit Alcohol intake 20 g per day case woman 30 g per day case men Hepatic virus infection Autoimmune , metabolic genetic liver disease Use drug know induce liver steatosis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>NAFLD</keyword>
	<keyword>metformin</keyword>
	<keyword>atorvastatin</keyword>
	<keyword>metabolic syndrome</keyword>
</DOC>